ClinicalTrials.gg
Status unknownNCT05480839Updated Jul 29, 2022

Manual Immediately Sequential Bilateral Cataract Surgery (M-ISBCS) vs Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS)

An interventional study of M-IBCS and ReLA-IBCS Early in MCS vs ReLACS, Pain Perception Postoperative and Early Anesthesia vs Standard Anesthesia, sponsored by Uptown Eye Specialists. Status unknown at 1 site in Canada. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by Uptown Eye Specialists · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Cataract with a site in Canada — 3 open to participants now, 3 under way, none of them phase 3. Cataract · Canada.

Planned enrollment
8th of 23
100 · median 68
Started
2022
with 2 others
No phase
18 of 33
1 open now
Registered
26th of 33
by date
Lead sponsor
5 of 33
Uptown Eye Specialists

Among the 33 studies in Cataract with a site in Canada, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2022, is one of 18 with no phase, and was the 26th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

3 of the 33 studies in Cataract with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Cataract with a site in Canada, or all of them as a file.
02

Study summary

The focus of this study is to assess the differences in patient perceptions of pain undergoing cataract surgery by using the Refractive Laser-Assisted Cataract Surgery (ReLACS) technique compared to the standard Manual Cataract Surgery (MCS) technique using an immediately sequential bilateral approach. This study also aims to further explore difference in patients' perceptions of pain depending on timing of neurolept anesthesia in the ReLACS technique. The importance of this study is appreciated patient perception of pain during ReLACS, which is an emerging technique for cataract surgery and has been sparsely reported on to date. This investigation will include the analysis of various surgical, ocular, medical, and psychosocial metrics of patients undergoing both ReLACS and MCS at Uptown Eye specialist.

03

Conditions studied

  • MCS vs ReLACS
  • Pain Perception Postoperative
  • Early Anesthesia vs Standard Anesthesia
  • Immediately Sequential Bilateral Cataract Surgery

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing uncomplicated cataract surgery with either surgical technique (M-ISBCS or ReLA-ISBCS)
  • Patients who require surgery in both eyes by the same surgeon
  • Able to understand English and complete a pain assessment (NRS)

Exclusion criteria

Exclusion Criteria:

  • Deafness or communication disorder, known Dementia, Severe /Asthma (severe lung disorder), Severe OSA, Psychiatric or Anxiety conditions, involuntary movement disorders, allergy to the anesthesia, any conditions requiring intraoperative iris manipulation, any prior ocular surgery
  • Pre-existing chronic eye pain or uveitis, or complicated cataracts (dislocation, zonulopathy)
  • Pre-existing uncontrolled glaucoma/high IOP
  • Intraoperative complications or non-routine cataracts (eg. Sutures, excessive time of surgery)
  • Any patient who requires Deep Sedation (Propofol), GA or preOP Ativan
  • Patients under 40, severe obesity ( >35)
  • Chronic pain/narcotics/recreational or medical marijuana
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Manual Immediately Sequential Bilateral Cataract Surgery (MCS)

    Procedure: M-IBCS

  • Experimental
    Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Early

    Procedure: ReLA-IBCS Early

  • Experimental
    Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery (ReLA-ISBCS) Standard

    Procedure: ReLA-ISBCS

Interventions

  • ProcedureM-IBCS

    Manual Cataract Surgery - Phacoemulsification: removal of the eye lens and insertion of an intraocular lens implant

  • ProcedureReLA-IBCS Early

    Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with early administration of anesthesia

  • ProcedureReLA-ISBCS

    Refractive Laser-Assisted Immediately Sequential Bilateral Cataract Surgery - ReLA-IBSCS with standard administration of anesthesia

06

What researchers measure

Primary outcomes

  1. Pain Perception between Manual Immediately Sequential Bilateral Cataract Surgery (M-ISBCS) and Refractive Laser-Assisted Immediately Sequential Cataract Surgery (ReLA-ISCS)

    Pain perceptions of patients undergoing M-IBCS vs ReLA-ISBCS will be measured using the Numerical Rating Scale (NRS) with pain ratings from 0 to 10.

    Time frame: 1 year

Secondary outcomes

  1. Effects of Early vs Standard administration of topical neurolept anesthesia on pain perception

    Pain perceptions of patients undergoing ReLA-ISBCS Early vs ReLA-ISBCS Standard will be measured using the Numerical Rating Scale (NRS) with pain ratings from 0 to 10.

    Time frame: 1 Year

07

Study locations

1 of 1 sites recruiting
  • Uptown Eye Specialist
    Brampton, Ontario L6Y0P6, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Aug 2022, 2 months after the start.

Of 304 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's planned 2 months is below that.

Counting every sponsor, half of 494 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2022
First posted
Jul 29, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Aug 31, 2022
CompletionEst.
Aug 31, 2022
Last update
Jul 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05480839
Lead sponsor
Uptown Eye Specialists
Responsible party
Sponsor
First posted
Jul 29, 2022
Start date
Jun 1, 2022
Primary completion
Aug 31, 2022 (estimated)
Completion
Aug 31, 2022 (estimated)
Last update
Jul 29, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion